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Abstract The rarity of severe complications of this disease in
children makes randomized clinical trials in immune throm-
bocytopenia (ITP) unfeasible. Therefore, the current manage-
ment recommendations for ITP are largely dependent on
clinical expertise and observations. As part of its discussions
during the Intercontinental Cooperative ITP Study Group
Expert Meeting in Basel, the Management working group
recommended that the decision to treat an ITP patient be
individualized and based mainly on bleeding symptoms and
not on the actual platelet count number and should be
supported by bleeding scores using a validated assessment
tool. The group stressed the need to develop a uniform
validated bleeding score system and to explore new
measures to evaluate bleeding risk in thrombocytopenic
patients—the role of rituximab as a splenectomy-sparing
agent in resistant disease was also discussed. Given the
apparently high recurrence rate to rituximab therapy in
children and the drug's possible toxicity, the group felt that
until more data are available, a conservative approach may
be considered, reserving rituximab for patients who failed
splenectomy. More studies of the effectiveness and side
effects of drugs to treat refractory patients, such as TPO
mimetics, cyclosporine, mycophenolate mofetil, and cyto-
toxic agents are required, as are long-term data on post-
splenectomy complications. In the patient with either acute
or chronic ITP, using a more personalized approach to
treatment based on bleeding symptoms rather than platelet
count should result in less toxicity and empower both
physicians and families to focus on quality-of-life.
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Introduction
Immune-mediated thrombocytopenia (ITP) is an acquired
disease of children and adults characterized by a transient or
persistent decrease in platelet count and increased risk of
bleeding. The rarity of severe complications of the disease in
children makes randomized clinical prevention trials unfea-
sible [1]. Therefore, at present, definitions of disease severity
and recommendations for management are largely dependent
on clinical expertise and observations and vary considerably
between countries [1, 2].
The Management Working group at the 2009 Interconti-
nental Cooperative ITP StudyGroup (ICIS) ExpertMeeting in
Basel discussed management milestones in ITP therapy. The
group suggested that the decision to treat a patient with ITP be
individualized and based mainly on bleeding symptoms and
guided by patient quality-of-life. The role of rituximab as a
splenectomy-sparing agent in refractory patients was
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reviewed in respect to efficacy and toxicity as were other less
commonly used regimens such as chemotherapy or TPO
mimetics. The best treatment for patients with chronic,
resistant disease is still unclear, partly because of a lack of
clinical and long-term follow-up data.
First milestone
Observation or intervention in severely thrombocytopenic
patients
Decisions regarding the management of ITP have traditionally
been made on the basis of the platelet count. Patients typically
present with severe thrombocytopenia at diagnosis (platelet
count <20,000/mm3), and physicians, associating the low
platelet count with a high risk of hemorrhage, often
administer drug therapy. The ICIS Registry data suggest,
however, that the incidence of intracranial hemorrhage, the
most severe complication of childhood ITP and the primary
cause of death, is very low, in the range of 0.17% of affected
children [3]. A similarly low figure of 0.2% was reported by
Lilleyman [4]. Bolton-Maggs and Moon [1, 4] found that the
majority of bleeding symptoms in ITP are relatively minor in
nature. Additionally, studies based on the ICIS prospective
registry indicated that even with profound thrombocytopenia
(platelet count ≤20,000/mm3), severe bleeding is uncommon
at diagnosis (2.9%), and it occurs only rarely during the next
4 weeks (0.6%), irrespective of the treatment given [5].
Given there is minimal-to-no hemorrhage in most patients
with ITP, specific descriptive [1], or semiquantitative [6, 7]
bleeding scoring systems have been developed. Using a
descriptive approach, Bolton-Maggs and Moon [4] divided
bleeding signs in newly diagnosed patients into four
categories: none, mild, moderate, and severe [1]. Buchanan
and Adix [5] formulated a bleeding score that assessed four
domains: overall bleeding tendency, bleeding from the oral
cavity, epistaxis, and cutaneous hemorrhage. Each site was
graded from 0 (no bleeding) to 4 (severe bleeding). Both these
instruments yielded a 3% rate of severe hemorrhage in
patients with ITP [4, 5]. However, neither has been validated
in a large prospective study.
Working group discussion
The working group recommended that the decision to treat a
patient with ITP should not be based on number of platelets;
rather, it should be individualized and based mainly on
bleeding symptoms, supported by bleeding scores (Fig. 1). In
the absence of hemorrhage, i.e., a bleeding score of 0–3 [6]
or a rating of mild to moderate [1], close observation alone
may be sufficient. The rare danger of severe bleeding and the
side effects of treatment should be discussed at length with the
family, and the parents should be educated to look for signs of
bleeding and to rapidly return to the hospital should they occur.
There are extenuating circumstances that might prompt the
physician to treat despite the absence of significant bleeding
symptoms. If the family is geographically isolated or unable to
closely observe the child, the clinician should consider
treatment to increase the platelet count above 20,000/mm3
and shorten the duration of thrombocytopenia. Age should
also be taken into account: an active toddler who constantly
bumps into things may need therapy whereas an older child
with the same bleeding pattern may not. Another major
factor is quality-of-life; for example, a young athlete may
need therapy to prevent bleeding into vital organs. In the
Fig. 1 Individualized decision
making in ITP therapy.
Circumstances in which
decision to treat patients despite
the absence of active bleeding
are highlighted
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adult or child, the presence of other co-morbidities,
especially those necessitating antiplatelet drugs (coronary
stent, cerebrovascular disease), may be an indication to
initiate therapy. Whether observing or treating, measures
should be taken to correct iron deficiency anemia in order to
elevate hemoglobin and improve viscosity. Conversely, the
use of anti-fibrinolytic therapy should be advocated to avoid
additional risks of bleeding in conjunction with the decreased
platelet count.
Even if the clinician decided not to commit the patient to
long-term therapy, many felt that it would be reasonable to
find a treatment to which the patient is responsive initially, so
that it can be applied promptly in case of an urgent need to
increase platelet counts (e.g., traumatic episode or surgery).
The working group stressed the need for a uniform
validated bleeding score system in ITP. Until one is
developed, the group suggested that current bleeding scores
be used consistently in the initial and ongoing assessments
of each patient. The results will contribute to the decision to
initiate therapy and are a prerequisite for prospective and
retrospective data evaluation. Methods for evaluation of
platelet functions in thrombocytopenic patients using global
clotting measures such as thrombin generation, rotational
thromboelastography, and microparticles enumeration
should be explored to find an additional means to assess
overall bleeding risk.
Second milestone
Therapy and its side effects
When ITP therapy is required, the first-line drugs com-
monly include steroids, intravenous immunoglobulin, or
anti-D immunoglobulin. The working group suggested that
if steroids are used, only a short course should be
administered in order to avoid the well-known adverse
effects of protracted corticosteroid therapy.
Treatment of ITP is indicated in only the minority of
patients who have low platelet counts associated with
bleeding symptoms. First-line ITP medications have been
administered to patients with chronic disease on a monthly
basis. In a small group of patients, second-line drugs (e.g.,
rituximab) or splenectomy may be considered. The decision
should be individualized for the patient and his family, taking
into account the high rate of spontaneous remission in
childhood ITP [8], quality-of-life parameters, and treatment
side effects. Splenectomy is successful in approximately
75% of pediatric patients [9]. However, the use of surgery
has declined due to increased awareness of the natural
history of the disease, the inability to predict a positive
outcome following surgery, and the irreversible nature of the
procedure coupled to the slight increased risk of sepsis [10].
In patients who fail splenectomy, cyclosporine [11],
mycophenolate mofetil [12], 6-mercaptopurine [13], vincris-
tine, and cyclophosphamide [14] have all been tried, with
variable results. Prospective studies are difficult to conduct
given the relative rarity of severe chronic ITP, its multiple
treatment approaches, and the spontaneous remissions that
may occur without medical therapy.
The sections that follow summarize working group
discussions surrounding some controversial issues in chronic
ITP therapy, including the role of rituximab and its potential to
spare patients splenectomy. They highlighted the need for
more data on the effectiveness and side effects of drugs such
as cyclophosphamide, mycophenolate mofetil, and cytotoxic
agents as well as long-term data on post-splenectomy
complications including the possible occurrence of thrombotic
complications [15].
Rituximab therapy in ITP
Rituximab is a chimeric human–mouse monoclonal anti-
body directed against the CD20 antigen on the surface of B
lymphocytes. Because it induces B-cell destruction, it is
assumed to stop the production of autoantibodies and
platelet destruction [16]. The drug is usually well tolerated
with minimal side effects. However, although the response
rate to treatment is initially relatively high (40–60%), only
15–20% of adult patients sustain a good response for at
least 3 years [17]. In children, only a few studies have
examined the long-term results of rituximab, and the
response rate ranged from 30% to 60% [18, 19].
The number of repeated courses of rituximab that may
be given, their efficacy, and side effects are not well known.
Furthermore, the effectiveness of a lower-than-standard
dose (375 mg/m2 every 7 days for 4 weeks) remains
unclear. One study reported that a lower dose of rituximab,
100 mg IV weekly for 4 weeks, had similar activity to the
standard dose [20].
Further research is needed to determine if rituximab can
effectively and safely prevent the need for splenectomy.
Only one study of 60 adult patients yielded promising
results [21].
In February 2006, 9 years after the drug received its initial
Food and Drug Administration approval, the labeling for
rituximab was changed, because patients with non-Hodgkin
lymphoma had developed serious viral infections after
treatment with the drug. The infections included hepatitis B,
cytomegalovirus, herpes simplex virus, varicella zoster virus,
West Nile virus, and JC virus [22]. A recent study described
the development of progressive multifocal leukoencephalop-
athy, a rare demyelinating disease of the central nervous
system caused by reactivation of latent JC polyoma virus,
following rituximab treatment, in one patient with ITP and in
57 patients with mostly lymphoid malignancies [23].
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Working group discussion
Given the general impression that the response rate to
rituximab is disappointingly low in children with ITP,
together with concerns regarding the drug's toxicity and
reports of progressive leukoencephalopathy, the working
group suggested that until more data become available, a
more conservative approach may be considered, reserving
rituximab for patients who fail splenectomy. More data are
needed to guide physicians in the optimal dose and whether
it requires division into four weekly doses as well.
Reimmunization and antibiotic prophylaxis
following splenectomy
Splenectomy poses an increased risk of septic complica-
tions which are associated with a high mortality rate. The
most serious complication is overwhelming post-
splenectomy infection, although its frequency has dropped
due to aggressive pneumococcal vaccination, prophylactic
penicillin, and prompt administration of parenteral anti-
biotics when fever occurs [24–26].
Working group discussion
At present, the immunization schedule after splenectomy is
based on expert opinion and is not evidence-based. In the
USA, experts recommend that immunization with the 23-
valent pneumococcal vaccine be repeated once, 5 years
after the initial dose. However, this practice, as well as the
duration of oral penicillin prophylaxis, varies among
countries. There is a need for long-term follow-up studies
of splenectomized patients and for uniform recommenda-
tions which can be prospectively evaluated.
Thrombopoietin–mimetic therapy
The newly developed second-generation thrombopoietin-
receptor agonists, eltrombopag and romiplostim, have been
shown to safely increase and maintain platelet production in
adult patients with refractory ITP [27]. However, the long-
term side-effects are still being assessed, and the exact role
of these agents in the overall treatment strategy of chronic
ITP remains to be established. After discontinuation of
therapy, the platelet count returns to baseline in the majority
of patients. Optimal weaning schedule has not been studied,
and there is no prospective means to identify which patients
might sustain their own platelet count without these
medications. Studies to evaluate the use of TPO mimetics
in combination with immune modulation may improve
long-term outcome of all medications.
As the TPO-mimetic drugs are still not approved for use
in children, most participants in the working group had had
no experience with them. Questions regarding their appli-
cation were, therefore, not discussed at length.
Third milestone
Health-related quality-of-life
Physicians caring for patients with ITP tend to focus on the
platelet count rather than bleeding symptoms and may fail
to appreciate the adverse effect of the treatment side effects
on patient and family quality-of-life. Studies in the USA
have shown that the health-related quality-of-life (HRQOL)
of adults with ITP was significantly worse than that of the
general population and scored similar to findings in patients
with chronic diseases, such as arthritis and diabetes [28,
29].
A modified HRQOL tool for use in children (Kid’s ITP
Tool) was recently developed and validated [30]. The
results suggested that quality-of-life of children with ITP
is not significantly affected by the platelet count. Thus, it is
apparently not the number of platelets per se that exerts the
overall disease impact on patients and their family, but
rather other factors, such as the restrictions in activity,
medication side effects, multiple clinic visits, and veni-
punctures for laboratory studies. Applying both bleeding
severity and HRQOL tools would be beneficial in guiding
clinical decisions [31] and improve overall quality-of-life
for these patients.
Prompted by these findings, the working group sug-
gested that the assessment of therapeutic effectiveness
should take patient and family quality-of-life into account.
Indeed, the success of ITP therapy should be redefined as
the ability of the patient to live life to the fullest, with
minimal impact from the treatment or the disease. To
achieve this goal, more quality-of-life data need to be
gathered in this important field with collaborative studies
incorporating the validated bleeding score and treatment
regimens versus observation alone.
Conclusions and future directions
The working group recommends that the decision to treat a
patient with ITP be based on the presence of active
bleeding and not on the platelet count. Bleeding tendency
should be further assessed by user-friendly validated
bleeding scores, which are currently not widely used. The
decision to treat or not to treat a severely thrombocytopenic
patient needs to be family based and individualized, taking
specific risk factors such as geographic isolation, age, co-
morbidities, and quality-of-life into consideration. In
addition, more time should be spent with the family to
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carefully educate and explain the risks of observation alone
versus therapy, drug side effects, and toxicities.
The decision to use specific second-line therapy should
also be individualized. The effectiveness of therapy should
be assessed regularly with ITP-QOL studies. Future
development of specific methods to assess the risk of
bleeding in thrombocytopenic patients using global clotting
assays will further improve patient management.
In view of the recent report of neurological complica-
tions induced by rituximab, multiple cycles of this drug
should probably not be given prior to splenectomy, which
by contrast is relatively safe with immunizations and has a
long-term resolution of thrombocytopenia in 75% of
patients. More clinical studies are indicated to define the
role of rituximab therapy in chronic ITP. In light of the
varied approach to prophylaxis, it is anticipated that long-
term follow-up data through ICIS will help to fully evaluate
splenectomy complications. Future use of TPO-mimetic
agents in children, although not curative alone, may be
beneficial in refractory cases.
Overall, the working group credited the efforts of ICIS
investigators in providing the much-needed data to shift the
focus from platelet count to bleeding phenotype and
anticipated that future meetings will evaluate the results of
collaborative work in the validation and utility bleeding
scores as well as the impact of therapeutic choices in the
quality-of-life for patients and families.
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